Prognostic markers for kidney cancer

A recent study published in the Lancet Oncology has identified that the mutation status of three genes – BAP1, PBRM1, and TP53 – had independent prognostic value for patients with advanced or metastatic renal cell carcinoma (RCC) about to start treatment with first-line tyrosine kinase inhibitors (TKIs). The mutation status of these three genes is useful for helping to determine […]

read more

Exercise significantly cuts the risk of death from cancer

New research from an American group based at Roswell Park Comprehensive Cancer Center, New York shows that if cancer patients exercise regularly both before and after their diagnosis, they are significantly more likely to survive cancer than those who are sedentary. This adds to the growing evidence that physical activity is important for the prevention […]

read more

Cancer drugs taking longer to reach NHS patients

A new report by the Institute of Cancer Research (ICR) has found that patients are waiting longer for new cancer drugs to be approved for use with the NHS because of delays in clinical trials and regulatory approval for use. The report found that the average time taken from the start of phase I clinical […]

read more

First NHS cancer patient to begin treatment with proton beam therapy in Manchester

Cally Palmer, NHS England’s national cancer director announced at the Britain Against Cancer conference yesterday that the first patient in England is to begin state of the art proton beam therapy for cancer at The Christie Hospital in Manchester this month, marking a major milestone for NHS care. The second proton beam therapy machine is […]

read more

Comparison of axitinib and sunitinib as first-line treatment for metastatic kidney cancer

This multicentre analysis of axitinib versus sunitinib used as first-line treatment for metastatic renal cell carcinoma (RCC) in 169 patients shows that compared with sunitinib, axitinib significantly prolonged cancer-specific survival and overall survival. Axitinib also had a safer adverse event profile compared to sunitinib as a first-line therapy for previously untreated metastatic RCC. Read the […]

read more

Robot-assisted surgery available in East Lancashire

Three talented surgeons have performed what is believed to be the first combined renal and bowel cancer surgery in the North West using robotic surgery assisted by the Da Vinci robot. The surgery was performed at the Royal Blackburn Teaching Hospital, East Lancashire Hospitals NHS Trust. The patient was given pioneering surgery involving a partial […]

read more
Showing 1 to 6 of 489 results